Apricus Biosciences (NASDAQ:APRI)

pchop123 (76.57) Submitted: 5/20/2013 12:16:15 PM : Start Price: $3.34 APRI Score: -21.50

still a great investment at this price

zzlangerhans (99.78) Submitted: 3/22/2013 1:52:03 AM : Start Price: $2.48 APRI Score: -2.43

It seems that the coast is clear for Vitaros and Femprox hype to start moving Apricus back into the 3's. Of course, this would be a very risky trade in real life as I believe Vitaros will prove to be uncompetitive with other products for erectile dysfunction and Femprox is unlikely to ever be commercialized. But with PrevOnco and MycoVa quiescent, the pipeline components most susceptible to bad news aren't likely to interfere with a strong dose of sex drug hype I'm expecting within the next few months.

thedrew1125 (55.78) Submitted: 2/23/2013 10:58:41 PM : Start Price: $2.70 APRI Score: -12.75

Gotta give some love to local San Diego companies. That easily-absorbed molecule that they put in their topical treatments will hopefully get some more use.

etra (< 20) Submitted: 11/17/2012 4:33:26 PM : Start Price: $2.18 APRI Score: -1.53

At present most players of APRI stock buy and then sell almost on a daily basis.The company should convince investment groups that future earnings should enable them to carry the price to $5.00 ..

acts20 (46.72) Submitted: 3/25/2012 5:49:37 PM : Start Price: $2.96 APRI Score: -30.37

Room to roam

cubanstockpicker (< 20) Submitted: 8/25/2011 6:22:17 PM : Start Price: $3.97 APRI Score: -77.90

Name reputation alone makes sure founder gets only the best students and the brightest researchers to then turn over the best and brightest products. To then be bought out for more than enough to make us the (you get the idea) profit.

Allstar13913 (99.78) Submitted: 7/30/2011 10:15:59 PM : Start Price: $3.14 APRI Score: +40.10

Company that is using data-mining to hopefully show a failed drug has potential.

http://www.thestreet.com/_yahoo/story/11169285/1/biotech-data-mining-comes-up-empty.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA

WallSTcz (< 20) Submitted: 4/27/2011 3:06:10 PM : Start Price: $5.64 APRI Score: -76.44

Dale Carnegie once said: „Every business is about people“

Bassam Damaj, Ph.D / Apricus Biosciences CEO /
Dr. Damaj is a very knowledgeable and well respected professional in the field. In the early 2000s, he was approached by the U.S. government. The military was in search of a technology that could detect Anthrax and its level of infection in the human body. Remarkably, Dr. Damaj was able to deliver this kit—the first of its kind—in less than six months, winning him a U.S. Congressional Award in 2002. This is a testament to the respect and talents of the Apricus Bio leadership.

Roberto Crea, Ph.D. / Apricus Biosciences Director /
Dr. Crea was appointed to the Board in December 2009, and has over 30 years of experience in the biotechnology field as a scientist, investor and entrepreneur. He is one of the scientific co-founders of Genentech, founder of Creative Bio Molecules, Inc. (1982), Creagen, Inc. (1992), CreAgri (1998), Bioren (2002) and ProtElix (2005). Creagen, Inc. was merged into Neurex in 1994, which was then sold to Elan Pharmaceuticals for over $700 million. Pfizer successfully acquired Bioren in 2005. Dr. Crea received his Ph.D. in Biological Chemistry from the University of Pavia, Italy. He was also an Associate Professor of DNA Chemical Synthesis at Leiden University in the Netherlands prior to moving to the U.S. in 1977. Dr. Crea is the author of more than 25 international patents and has co-authored more than 50 scientific articles. He was also the recipient of the Rumbaugh Award for Scientific Contribution given by the Juvenile Diabetes Foundation for America.

josh28105 (< 20) Submitted: 2/23/2011 5:25:46 AM : Start Price: $5.09 APRI Score: -74.78

This stock has a lot of good things coming out.

THEMATHISNEAR (< 20) Submitted: 2/17/2011 10:15:30 AM : Start Price: $4.33 APRI Score: +72.48

Shorting a bunch of rickety-financed biotechs that have run up for no reason. Yes, I expect one to pop, and don't know which one, but I expect that most will fail outright, and the group as a whole will fail to match the S&P.

dmacin (< 20) Submitted: 2/16/2011 9:52:24 PM : Start Price: $4.20 APRI Score: -62.43

Seems to be moving

dustinmoh6 (< 20) Submitted: 11/23/2010 10:23:07 PM : Start Price: $3.22 APRI Score: -59.72

Apricus's unique NexACT technology could prove to be very valuable, both from their own drugs and out-licensing to other companies to use. The company has a large arsenal of drugs covering a wide array of health issues. More importantly Apricus's first approved drug, Vitaros, could be a huge winner in the large ED market. It looks as if the company has turned a corner.

dustinm06 (< 20) Submitted: 11/23/2010 9:39:05 AM : Start Price: $3.49 APRI Score: -65.04

Apricus retains a very innovative core technology called NexACT. This can be blended with already known and effective treatments. NexACT helps these compounds be better absorbed in the body and allows multiple routes of delivery. With an already approved drug, Vitaros, the company has a proven and clinically validated technology it will leverage and monetize.